title: Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome.
abstract: Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.
authors: Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France.
authors: Mouna
authors: M
authors: Ben Djebara
authors: Yulia
authors: Y
authors: Worbe
authors: Michael
authors: M
authors: Schüpbach
authors: Andreas
authors: A
authors: Hartmann
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D006801:Humans; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D005879:Tourette Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole